Progresses in clinical research of heavy ion therapy for cancer

doi:10.3760/cma.j.cn371439-20200117-00112

Abstract

Wang Shan, Li Ping, Zhang Rui, Han Jianglong, Hu Qinyong, Fu Zhenming. Progresses in clinical research of heavy ion therapy for cancer[J]. Journal of International Oncology, 2020, 47(12): 741-745.

References 31

[1]	王岚, 戴小亚. 全球质子重离子医院现状与展望[J]. 中国医院建筑与装备, 2016,14(1):27-31. DOI: 10.3969/j.issn.1671-9174.2016.01.002.
[2]	Wilson RR. Radiological use of fast protons[J]. Radiology, 1946,47(5):487-491. DOI: 10.1148/47.5.487. doi: 10.1148/47.5.487 pmid: 20274616
[3]	Kamada T. Twenty years of carbon ion radiation therapy at the national institute of radiological sciences: accomplishments and prospects[J]. Int J Part Ther, 2016,2(3):459-463. DOI: 10.14338/IJPT-15-00030.1. doi: 10.14338/IJPT-15-00030.1 pmid: 31772956
[4]	Durante M, Orecchia R, Loeffler JS. Charged-particle therapy in cancer: clinical uses and future perspectives[J]. Nat Rev Clin Oncol, 2017,14(8):483-495. DOI: 10.1038/nrclinonc.2017.30. doi: 10.1038/nrclinonc.2017.30 pmid: 28290489
[5]	Mohamad O, Makishima H, Kamada T. Evolution of carbon ion radiotherapy at the national institute of radiological sciences in Japan[J]. Cancers (Basel), 2018,10(3):66. DOI: 10.3390/cancers10030066. doi: 10.3390/cancers10030066
[6]	Mohamad O, Sishc BJ, Saha J, et al. Carbon ion radiotherapy: a review of clinical experiences and preclinical research, with an emphasis on DNA damage/repair[J]. Cancers (Basel), 2017,9(6):66. DOI: 10.3390/cancers9060066. doi: 10.3390/cancers9060066
[7]	Tsujii H, Mizoe JE, Kamada T, et al. Overview of clinical expe-riences on carbon ion radiotherapy at NIRS[J]. Radiother Oncol, 2004,73 Suppl 2: S41-S49. DOI: 10.1016/s0167-8140(04)80012-4.
[8]	Nomiya T, Tsuji H, Kawamura H, et al. A multi-institutional analysis of prospective studies of carbon ion radiotherapy for prostate can-cer: a report from the Japan Carbon ion Radiation Oncology Study Group (J-CROS)[J]. Radiother Oncol, 2016,121(2):288-293. DOI: 10.1016/j.radonc.2016.10.009. doi: 10.1016/j.radonc.2016.10.009 pmid: 27836119
[9]	Kim JY, Byun SJ, Kim YS, et al. Disease courses in patients with residual tumor following concurrent chemoradiotherapy for locally advanced cervical cancer[J]. Gynecol Oncol, 2017,144(1):34-39. DOI: 10.1016/j.ygyno.2016.10.032. doi: 10.1016/j.ygyno.2016.10.032 pmid: 27789082
[10]	Okonogi N, Wakatsuki M, Kato S, et al. A phase 1/2 study of carbon ion radiation therapy with concurrent chemotherapy for locally advanced uterine cervical squamous cell carcinoma (protocol 1302)[J]. Int J Radiat Oncol Biol Phys, 2019,104(3):631-639. DOI: 10.1016/j.ijrobp.2019.02.042. doi: 10.1016/j.ijrobp.2019.02.042 pmid: 30825494
[11]	Okonogi N, Wakatsuki M, Kato S, et al. Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (protocol 1001)[J]. Cancer Med, 2018,7(2):351-359. DOI: 10.1002/cam4.1305. doi: 10.1002/cam4.1305 pmid: 29341491
[12]	Mizoe JE. Review of carbon ion radiotherapy for skull base tumors (especially chordomas)[J]. Rep Pract Oncol Radiother, 2016,21(4):356-360. DOI: 10.1016/j.rpor.2015.01.008. pmid: 27330420
[13]	Takagi M, Demizu Y, Hashimoto N, et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck[J]. Radiother Oncol, 2014,113(3):364-370. DOI: 10.1016/j.radonc.2014.11.031. doi: 10.1016/j.radonc.2014.11.031
[14]	Morimoto K, Demizu Y, Hashimoto N, et al. Particle radiotherapy using protons or carbon ions for unresectable locally advanced head and neck cancers with skull base invasion[J]. Jpn J Clin Oncol, 2014,44(5):428-434. DOI: 10.1093/jjco/hyu010. doi: 10.1093/jjco/hyu010
[15]	Kamada T, Tsujii H, Blakely EA, et al. Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience[J]. Lancet Oncol, 2015,16(2):e93-e100. DOI: 10.1016/S1470-2045(14)70412-7.
[16]	Shinoto M, Yamada S, Okamoto M, et al. Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) study 1404 rectum[J]. Radiother Oncol, 2019,132:236-240. DOI: 10.1016/j.radonc.2018.10.007.
[17]	Qi WX, Fu S, Zhang Q, et al. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis[J]. Radiother Oncol, 2015,114(3):289-295. DOI: 10.1016/j.radonc.2014.11.033. pmid: 25497556
[18]	Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepatocellular carcinoma[J]. World J Gastroenterol, 2014,20(12):3100-3111. DOI: 10.3748/wjg.v20.i12.3100. pmid: 24696597
[19]	Yasuda S, Kato H, Imada H, et al. Long-term results of high-dose 2-fraction carbon ion radiation therapy for hepatocellular carcinoma[J]. Adv Radiat Oncol, 2019,5(2):196-203. DOI: 10.1016/j.adro.2019.09.007.
[20]	Robin TP, Goodman KA. Radiation therapy in the management of pancreatic adenocarcinoma: review of current evidence and future opportunities[J]. Chin Clin Oncol, 2017,6(3):28. DOI: 10.21037/cco.2017.06.12.
[21]	Shinoto M, Yamada S, Terashima K, et al. Carbon ion radiation therapy with concurrent gemcitabine for patients with locally advanced pancreatic cancer[J]. Int J Radiat Oncol Biol Phys, 2016,95(1):498-504. DOI: 10.1016/j.ijrobp.2015.12.362. doi: 10.1016/j.ijrobp.2015.12.362 pmid: 26883565
[22]	Mohamad O, Yamada S, Durante M. Clinical indications for carbon ion radiotherapy[J]. Clin Oncol (R Coll Radiol), 2018,30(5):317-329. DOI: 10.1016/j.clon.2018.01.006.
[23]	Kawashiro S, Yamada S, Okamoto M, et al. Multi-institutional study of carbon-ion radiotherapy for locally advanced pancreatic cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) study 1403 pancreas[J]. Int J Radiat Oncol Biol Phys, 2018,101(5):1212-1221. DOI: 10.1016/j.ijrobp.2018.04.057. doi: 10.1016/j.ijrobp.2018.04.057 pmid: 29907490
[24]	Isozaki Y, Yasuda S, Akutsu Y, et al. Salvage carbon-ion radio-therapy for isolated lymph node recurrence following curative resection of esophageal cancer[J]. Anticancer Res, 2018,38(11):6453-6458. DOI: 10.21873/anticanres.13007.
[25]	Yamamoto N, Miyamoto T, Nakajima M, et al. A dose escalation clinical trial of single-fraction carbon ion radiotherapy for peripheral stage Ⅰ non-small cell lung cancer[J]. J Thorac Oncol, 2017,12(4):673-680. DOI: 10.1016/j.jtho.2016.12.012. pmid: 28007628
[26]	Karube M, Yamamoto N, Tsuji H, et al. Carbon-ion re-irradiation for recurrences after initial treatment of stage Ⅰ non-small cell lung cancer with carbon-ion radiotherapy[J]. Radiother Oncol, 2017,125(1):31-35. DOI: 10.1016/j.radonc.2017.07.022.
[27]	Shirai K, Kawashima M, Saitoh JI, et al. Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-a pilot study[J]. PLoS One, 2017,12(4):e0175589. DOI: 10.1371/journal.pone.0175589. doi: 10.1371/journal.pone.0175589 pmid: 28399182
[28]	Coggins WS, Pham NK, Nguyen AV, et al. A systematic review of ion radiotherapy in maintaining local control regarding atypical and anaplastic meningiomas[J]. World Neurosurg, 2019,132:282-291. DOI: 10.1016/j.wneu.2019.08.149.
[29]	EI Shafie RA, Czech M, Kessel KA, et al. Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning[J]. Radiat Oncol, 2018,13(1):54. DOI: 10.1186/s13014-018-1002-5.
[30]	Malouff TD, Peterson JL, Mahajan A, et al. Carbon ion radio-therapy in the treatment of gliomas: a review[J]. J Neurooncol, 2019,145(2):191-199. DOI: 10.1007/s11060-019-03303-y. doi: 10.1007/s11060-019-03303-y
[31]	Demizu Y, Jin D, Sulaiman NS, et al. Particle therapy using protons or carbon ions for unresectable or incompletely resected bone and soft tissue sarcomas of the pelvis[J]. Int J Radiat Oncol Biol Phys, 2017,98(2):367-374. DOI: 10.1016/j.ijrobp.2017.02.030.

Progresses in clinical research of heavy ion therapy for cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.